BI Asset Management Fondsmaeglerselskab A S Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 43.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,449 shares of the medical equipment provider's stock after acquiring an additional 2,871 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Zimmer Biomet were worth $998,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Wilmington Savings Fund Society FSB grew its position in shares of Zimmer Biomet by 7.7% in the third quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider's stock valued at $669,000 after purchasing an additional 442 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its stake in Zimmer Biomet by 17.5% during the third quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider's stock worth $260,000 after acquiring an additional 358 shares during the last quarter. GAMMA Investing LLC raised its holdings in Zimmer Biomet by 67.6% in the fourth quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider's stock valued at $243,000 after buying an additional 927 shares during the period. Central Pacific Bank Trust Division raised its stake in shares of Zimmer Biomet by 7.4% in the 4th quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider's stock valued at $1,534,000 after acquiring an additional 1,000 shares during the period. Finally, Nordea Investment Management AB raised its position in Zimmer Biomet by 3.9% in the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider's stock valued at $1,732,000 after purchasing an additional 609 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZBH. Truist Financial restated a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Stock Up 1.4 %

ZBH stock opened at $97.51 on Wednesday. The firm has a market cap of $19.29 billion, a PE ratio of 21.91, a PEG ratio of 1.95 and a beta of 0.84. The company has a fifty day simple moving average of $105.82 and a 200 day simple moving average of $106.62. Zimmer Biomet Holdings, Inc. has a 1 year low of $93.10 and a 1 year high of $123.96. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business earned $2.20 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.